Affordable Access

An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.

Authors
  • Thakral, Parul
  • Singla, Suhas
  • Yadav, Madhav Prasad
  • Vasisht, Atul
  • Sharma, Atul
  • Gupta, Santosh Kumar
  • Bal, C S
  • Malhotra, Arun
Type
Published Article
Journal
The Indian Journal of Medical Research
Publisher
Medknow Publications
Publication Date
March 2014
Volume
139
Issue
4
Pages
544–554
Identifiers
PMID: 24927340
Source
Medline
License
Unknown

Abstract

A favourable radiochemical purity, stability and biodistribution of the radiolabelled immunoconjugate indicate that clinical trials for evaluation of toxicity and efficacy of 177 Lu-DOTA-antiCD20 antibody-Rituximab (BioSim) in patients of relapsed and refractory non Hodgkin's lymphoma can be considered.

Report this publication

Statistics

Seen <100 times